MA63458B1 - Nouveaux dérivés de sulfonamide pyrimidin-2-yl - Google Patents

Nouveaux dérivés de sulfonamide pyrimidin-2-yl

Info

Publication number
MA63458B1
MA63458B1 MA63458A MA63458A MA63458B1 MA 63458 B1 MA63458 B1 MA 63458B1 MA 63458 A MA63458 A MA 63458A MA 63458 A MA63458 A MA 63458A MA 63458 B1 MA63458 B1 MA 63458B1
Authority
MA
Morocco
Prior art keywords
pyrimidin
sulfonamide derivatives
new sulfonamide
new
compounds
Prior art date
Application number
MA63458A
Other languages
English (en)
Inventor
Antonio Ricci
Luca Gobbi
Wolfgang Guba
Guido Galley
Emmanuel Pinard
Dmitry MAZUNIN
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA63458B1 publication Critical patent/MA63458B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne de nouveaux composés de formule générale (I), dans laquelle R1, R2, R3, R4, X1 et X2 sont tels que définis dans la description, une composition comprenant ces composés et des procédés d'utilisation de ces composés.
MA63458A 2021-02-26 2022-02-24 Nouveaux dérivés de sulfonamide pyrimidin-2-yl MA63458B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21159452 2021-02-26
EP22707455.6A EP4298092B1 (fr) 2021-02-26 2022-02-24 Nouveaux dérivés de sulfonamide pyrimidin-2-yl
PCT/EP2022/054586 WO2022180136A1 (fr) 2021-02-26 2022-02-24 Nouveaux dérivés de pyrimidin-2-yl sulfonamide

Publications (1)

Publication Number Publication Date
MA63458B1 true MA63458B1 (fr) 2026-01-30

Family

ID=74797733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63458A MA63458B1 (fr) 2021-02-26 2022-02-24 Nouveaux dérivés de sulfonamide pyrimidin-2-yl

Country Status (27)

Country Link
US (1) US20240025883A1 (fr)
EP (2) EP4298092B1 (fr)
JP (1) JP2024507176A (fr)
KR (1) KR20230152006A (fr)
CN (1) CN116829550A (fr)
AR (1) AR124973A1 (fr)
AU (1) AU2022227183A1 (fr)
CA (1) CA3203282A1 (fr)
CL (1) CL2023002429A1 (fr)
CO (1) CO2023010212A2 (fr)
CR (1) CR20230410A (fr)
DK (1) DK4298092T3 (fr)
ES (1) ES3059608T3 (fr)
FI (1) FI4298092T3 (fr)
HR (1) HRP20260023T1 (fr)
IL (1) IL304450A (fr)
LT (1) LT4298092T (fr)
MA (1) MA63458B1 (fr)
MX (1) MX2023009045A (fr)
PE (1) PE20240125A1 (fr)
PL (1) PL4298092T3 (fr)
PT (1) PT4298092T (fr)
RS (1) RS67631B1 (fr)
SI (1) SI4298092T1 (fr)
TW (1) TW202245749A (fr)
WO (1) WO2022180136A1 (fr)
ZA (1) ZA202305344B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023129A1 (fr) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Nouveaux dérivés d'indole sulfonamide substitués en position 7
AR130023A1 (es) * 2022-07-28 2024-10-23 Hoffmann La Roche Derivados de indol sulfonamida 7 sustituidos
CN120476117A (zh) * 2022-11-20 2025-08-12 迈巴制药公司 Gpr17调节剂及其用途
AR131633A1 (es) 2023-01-20 2025-04-16 Hoffmann La Roche Derivados novedosos de pirimidinil sulfonamida
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2701173A (en) 2024-05-23 2026-04-22 Pheno Therapeutics Ltd Compounds
WO2026087899A1 (fr) * 2024-10-23 2026-04-30 Nxera Pharma Uk Limited Modulateurs du récepteur gpr17

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
TWI857957B (zh) * 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (fr) * 2018-06-20 2019-12-25 UCB Pharma GmbH Indolsulfonamides alkoxypyridinyl substitués
US20230373935A1 (en) * 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
MX2023009045A (es) 2023-08-10
JP2024507176A (ja) 2024-02-16
AU2022227183A9 (en) 2024-10-10
RS67631B1 (sr) 2026-02-27
TW202245749A (zh) 2022-12-01
AU2022227183A1 (en) 2023-06-22
DK4298092T3 (da) 2026-02-02
FI4298092T3 (fi) 2026-02-03
EP4298092B1 (fr) 2025-11-26
PL4298092T3 (pl) 2026-03-09
KR20230152006A (ko) 2023-11-02
IL304450A (en) 2023-09-01
HRP20260023T1 (hr) 2026-02-27
LT4298092T (lt) 2026-02-10
ZA202305344B (en) 2024-01-31
CR20230410A (es) 2023-09-25
CO2023010212A2 (es) 2023-09-08
EP4744661A2 (fr) 2026-05-20
ES3059608T3 (en) 2026-03-23
AR124973A1 (es) 2023-05-24
PE20240125A1 (es) 2024-01-22
PT4298092T (pt) 2026-01-06
US20240025883A1 (en) 2024-01-25
EP4298092A1 (fr) 2024-01-03
CN116829550A (zh) 2023-09-29
WO2022180136A1 (fr) 2022-09-01
CA3203282A1 (fr) 2022-09-01
SI4298092T1 (sl) 2026-04-30
CL2023002429A1 (es) 2024-01-12

Similar Documents

Publication Publication Date Title
MA64323B1 (fr) Inhibiteurs de nlrp3
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
TNSN06386A1 (fr) Derives de tetraazabenzo [e] azulene et leurs analogues
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN08196A1 (fr) Derives de pyrazine
MA31597B1 (fr) Nouveaux herbicides
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA31596B1 (fr) Nouveaux herbicides
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA31754B1 (fr) Cis-imidazolines chirales
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
MA31690B1 (fr) Nouveaux fongicides
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA29909B1 (fr) Derives de pyridazine
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih